AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12544402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine (PCV)
Number of subjects: 37868
Study 12544402 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 37868
Study 11018577 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8843257 — intervention group
Group type: EXPERIMENTAL
Intervention: HA membrane
Number of subjects: 183
Study 8843257 — intervention group
Group type: COMPARATOR
Intervention: Control (no HA membrane)
Number of subjects: 183
Study 1353134 — intervention group
Group type: EXPERIMENTAL
Intervention: ST waveform analysis plus CTG
Number of subjects: 1200
Study 1353134 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiotocography (CTG)
Number of subjects: 1200
Study 6504708 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomer combinations (10 mg (−) enantiomer + 40, 90, and 140 mg (+) enantiomer)
Number of subjects: 10
Study 6504708 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg)
Number of subjects: 10
Study 6504708 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomer combinations
Number of subjects: 10
Study 31892686 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF
Number of subjects: 54
Study 31892686 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF + Collaplug
Number of subjects: 54
Study 31892686 — intervention group
Group type: COMPARATOR
Intervention: No preservation
Number of subjects: 54
Study 29511971 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive blood pressure monitoring (CS group)
Number of subjects: 40
Study 29511971 — intervention group
Group type: COMPARATOR
Intervention: Intermittent BP cuff measurement (Control group)
Number of subjects: 40
Study 27270228 — intervention group
Group type: EXPERIMENTAL
Intervention: Tm1Tm2 (two different mediators)
Number of subjects: 0
Study 27270228 — intervention group
Group type: COMPARATOR
Intervention: Tm1Tm1 (one mediator)
Number of subjects: 0
Study 25018804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids
Number of subjects: 150
Study 25018804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral steroids
Number of subjects: 150
Study 25018804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 25018804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous steroids
Number of subjects: 150
Study 22331983 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamin B6 3 mg, vitamin B12 0.02 mg)
Number of subjects: 2501
Study 22331983 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids (eicosapentaenoic and docosahexaenoic acid 600 mg)
Number of subjects: 2501
Study 22331983 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins and ω-3 fatty acids
Number of subjects: 2501
Study 22331983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2501
Study 20642481 — intervention group
Group type: EXPERIMENTAL
Intervention: Double kissing (DK) crush
Number of subjects: 51
Study 20642481 — intervention group
Group type: COMPARATOR
Intervention: Provisional 1-stent
Number of subjects: 51
Study 17998836 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based education programme for patients with mild GORD
Number of subjects: 211
Study 17998836 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based education programme for patients with mild GORD (specifically for those with primary school education)
Number of subjects: 211
Study 17998836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education programme)
Number of subjects: 211
Study 15726309 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker clip placement at biopsy site
Number of subjects: 79
Study 12213517 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (AMPH; 15 mg oral)
Number of subjects: 20
Study 9708229 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound
Number of subjects: 6
Study 9708229 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude ultrasound angiography
Number of subjects: 6
Study 9708229 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time grey scale imaging
Number of subjects: 6
Study 9708229 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour Doppler ultrasound after embolotherapy
Number of subjects: 6
Study 9708229 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral wave analysis
Number of subjects: 6
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (continuous intravenous infusion)
Number of subjects: 0
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of anticoagulants
Number of subjects: 0
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of aspirin and NSAIDs
Number of subjects: 0
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusions to maintain platelet count above 50,000
Number of subjects: 0
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytics
Number of subjects: 0
Study 7745465 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena caval filters and thrombectomy
Number of subjects: 0
Study 2809170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% povidone-iodine
Number of subjects: 0
Study 2809170 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine
Number of subjects: 0
Study 2809170 — intervention group
Group type: COMPARATOR
Intervention: Plain detergent
Number of subjects: 0
Study 2809170 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 0
Study 31307527 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (a combination of aerobic and resistance training with progressive intensity and volume, three times per week during ACT)
Number of subjects: 90
Study 31307527 — intervention group
Group type: COMPARATOR
Intervention: Standard BC care (control group)
Number of subjects: 90
Study 31307527 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 90
Study 28647169 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day preschool vaccinations (number of injections between ages four and six years)
Number of subjects: 120
Study 28647169 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper quartile of needle fear (VAS≥83)
Number of subjects: 120
Study 28647169 — intervention group
Group type: COMPARATOR
Intervention: Parent vaccine anxiety (VAS>50)
Number of subjects: 120
Study 25405571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estradiol (E2) 0.5 mg/day
Number of subjects: 339
Study 25405571 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg/day
Number of subjects: 339
Study 25405571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 23644225 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with UPPP
Number of subjects: 65
Study 23644225 — intervention group
Group type: COMPARATOR
Intervention: Expectancy (control group)
Number of subjects: 65
Study 22013952 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of 20% albumin
Number of subjects: 10
Study 22013952 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of 4% gelatin
Number of subjects: 10
Study 22013952 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 10
Study 18818699 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34)
Number of subjects: 69
Study 18818699 — intervention group
Group type: COMPARATOR
Intervention: CHOP (n=30)
Number of subjects: 69
Study 16698659 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 123
Study 16698659 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 123
Study 16698659 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 15228864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine 0.75 ml/kg along with 0.1% midazolam 50mg/kg (group B)
Number of subjects: 60
Study 15228864 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine 0.75 ml/kg (group A)
Number of subjects: 60
Study 11953729 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter injections
Number of subjects: 41
Study 11953729 — intervention group
Group type: COMPARATOR
Intervention: Insulin pens with standard needles (Control)
Number of subjects: 41
Study 9832299 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg three times a day for 4 days)
Number of subjects: 9
Study 9832299 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once a day for 4 days)
Number of subjects: 9
Study 9832299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7867751 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant conditioning training for biceps brachii SSRs over 24 sessions in 8 weeks.
Number of subjects: 17
Study 7867751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training) during the same period.
Number of subjects: 17
Study 2553425 — intervention group
Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (35 micrograms)
Number of subjects: 7
Study 2553425 — intervention group
Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (17.5 micrograms)
Number of subjects: 7
Study 2553425 — intervention group
Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (8.75 micrograms)
Number of subjects: 7
Study 2553425 — intervention group
Group type: EXPERIMENTAL
Intervention: HPTH 1-38 (all doses)
Number of subjects: 7
Study 1026548 — intervention group
Group type: EXPERIMENTAL
Intervention: Forewarned about side-effects (Group A)
Number of subjects: 100
Study 1026548 — intervention group
Group type: COMPARATOR
Intervention: Not forewarned about side-effects (Group B)
Number of subjects: 100
Study 28859083 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker intervention (CHW integration with PMTCT services)
Number of subjects: 1
Study 28859083 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (comparison group)
Number of subjects: 1
Study 25504995 — intervention group
Group type: EXPERIMENTAL
Intervention: AICS-Bud 1 mg
Number of subjects: 199
Study 25504995 — intervention group
Group type: EXPERIMENTAL
Intervention: AICS-Bud 0.5 mg
Number of subjects: 199
Study 25504995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 25504995 — intervention group
Group type: COMPARATOR
Intervention: CN-Bud
Number of subjects: 199
Study 23131756 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg/kg ivermectin
Number of subjects: 6
Study 23131756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 23131756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 6
Study 21067837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of glimepiride
Number of subjects: 25
Study 21067837 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of glimepiride
Number of subjects: 25
Study 19580019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine scalp infiltration
Number of subjects: 36
Study 19580019 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 36
Study 17161520 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 278
Study 14994690 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis (computerised utility assessment interview with individualised risk assessment and decision analysis)
Number of subjects: 217
Study 14994690 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus leaflet
Number of subjects: 217
Study 14994690 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis plus video plus leaflet
Number of subjects: 217
Study 14994690 — intervention group
Group type: COMPARATOR
Intervention: No decision analysis
Number of subjects: 217
Study 14994690 — intervention group
Group type: COMPARATOR
Intervention: No video plus leaflet
Number of subjects: 217
Study 14994690 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis and video plus leaflet interaction
Number of subjects: 217
Study 14994690 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 217
Study 11320899 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms GM‐CSF in a 2% methylcellulose gel daily
Number of subjects: 36
Study 11320899 — intervention group
Group type: COMPARATOR
Intervention: 2% methylcellulose gel alone (placebo)
Number of subjects: 36
Study 11320899 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF group
Number of subjects: 36
Study 11320899 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36
Study 11320899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 9129083 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF), daily treatment over a 14-day period.
Number of subjects: 0
Study 8179852 — intervention group
Group type: EXPERIMENTAL
Intervention: lacidipine
Number of subjects: 18
Study 8179852 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31982355 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin epsilon 75 IU daily
Number of subjects: 247
Study 31982355 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin epsilon 112.5 IU
Number of subjects: 247
Study 31982355 — intervention group
Group type: COMPARATOR
Intervention: Follitropin alfa 150 IU daily
Number of subjects: 247
Study 31493887 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut sublingual immunotherapy (SLIT) with 2 mg/d peanut protein for up to 5 years
Number of subjects: 48
Study 26788484 — intervention group
Group type: EXPERIMENTAL
Intervention: BTX-A injection + EMG biofeedback
Number of subjects: 34
Study 26788484 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + EMG biofeedback
Number of subjects: 34
Study 26788484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BTX-A and control)
Number of subjects: 34
Study 23338814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate, 5 mg (N‐EST)
Number of subjects: 53
Study 23338814 — intervention group
Group type: COMPARATOR
Intervention: Control EST (C‐EST)
Number of subjects: 53
Study 21146572 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g scFOS
Number of subjects: 20
Study 21146572 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 g scFOS
Number of subjects: 20
Study 21146572 — intervention group
Group type: COMPARATOR
Intervention: 0 g scFOS (control)
Number of subjects: 20
Study 21146572 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath hydrogen measures
Number of subjects: 20
Study 21146572 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal tolerance evaluation
Number of subjects: 20
Study 18271887 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (misoprostol vaginally)
Number of subjects: 652
Study 18271887 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment (vacuum aspiration)
Number of subjects: 652
Study 16487998 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based smoking prevention curriculum with a social normative approach
Number of subjects: 7
Study 16487998 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched schools)
Number of subjects: 7
Study 12764372 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA protocol (all-trans retinoic acid and idarubicin)
Number of subjects: 134
Study 12764372 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDA protocol (consolidation therapy)
Number of subjects: 134
Study 12764372 — intervention group
Group type: EXPERIMENTAL
Intervention: amended AIDA protocol (aAIDA)
Number of subjects: 134
Study 12764372 — intervention group
Group type: COMPARATOR
Intervention: AIDA protocol
Number of subjects: 134
Study 11109030 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (paramedics operating protocol A)
Number of subjects: 1309
Study 11109030 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (paramedics operating protocol B)
Number of subjects: 1309
Study 11109030 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 1309
Study 11109030 — intervention group
Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 1309
Study 9186434 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 111
Study 9186434 — intervention group
Group type: COMPARATOR
Intervention: Contralateral eyes (control)
Number of subjects: 111
Study 1550219 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training plus growth hormone (GH)
Number of subjects: 16
Study 1550219 — intervention group
Group type: COMPARATOR
Intervention: Resistance training plus placebo
Number of subjects: 16
Study 2859841 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 24
Study 2859841 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulator setups
Number of subjects: 24
Study 30838389 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB based education program
Number of subjects: 140
Study 30838389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 30144888 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelly filled doughnut with water consumed 30 minutes after the doughnut (Group B)
Number of subjects: 35
Study 30144888 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelly filled doughnut with water consumed 30 minutes before the doughnut (Group C)
Number of subjects: 35
Study 30144888 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelly filled doughnut with water consumed 30 minutes after the first doughnut (Group D)
Number of subjects: 35
Study 30144888 — intervention group
Group type: EXPERIMENTAL
Intervention: Jelly filled doughnut with water consumed 30 minutes after the first doughnut (Group E)
Number of subjects: 35
Study 30144888 — intervention group
Group type: COMPARATOR
Intervention: Jelly filled doughnut without water (Group A)
Number of subjects: 35
Study 26802917 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching group
Number of subjects: 0
Study 26802917 — intervention group
Group type: COMPARATOR
Intervention: Self‐directed learning group
Number of subjects: 0
Study 26802917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 25043862 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone-releasing hydrogel applied epicardially
Number of subjects: 100
Study 25043862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amiodarone hydrogel)
Number of subjects: 100
Study 25043862 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone-releasing hydrogel
Number of subjects: 100
Study 23469596 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture combined with general intravenous anesthesia (Group D)
Number of subjects: 40
Study 23469596 — intervention group
Group type: COMPARATOR
Intervention: General intravenous anesthesia (Group N)
Number of subjects: 40
Study 20406937 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) treatment after induction in patients overexpressing G-CSFR isoform IV
Number of subjects: 154
Study 20406937 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) treatment after induction
Number of subjects: 154
Study 20406937 — intervention group
Group type: COMPARATOR
Intervention: No G-CSF treatment
Number of subjects: 154
Study 17276748 — intervention group
Group type: EXPERIMENTAL
Intervention: DD‐CGAS
Number of subjects: 83
Study 16318774 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN including GLN dipeptide
Number of subjects: 40
Study 16318774 — intervention group
Group type: COMPARATOR
Intervention: TPN
Number of subjects: 40
Study 12040303 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk-and-talk group (30 min, 5 times per week for 16 weeks, walking/talking in pairs)
Number of subjects: 3
Study 12040303 — intervention group
Group type: COMPARATOR
Intervention: Talk-only group (30 min, 5 times per week for 16 weeks, talk only in pairs)
Number of subjects: 3
Study 12040303 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 3
Study 10215749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine (30 g over 30 min)
Number of subjects: 10
Study 10215749 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (10 g)
Number of subjects: 10
Study 10215749 — intervention group
Group type: COMPARATOR
Intervention: Control study (normal diet, n = 12)
Number of subjects: 10
Study 8592593 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration at 35.0 degrees C
Number of subjects: 12
Study 8592593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ultrafiltration-haemodialysis at 37.5 degrees C
Number of subjects: 12
Study 8592593 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ultrafiltration-haemodialysis at 35.0 degrees C
Number of subjects: 12
Study 8592593 — intervention group
Group type: COMPARATOR
Intervention: Combined ultrafiltration-haemodialysis at both temperatures
Number of subjects: 12
Study 2092028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 gm T.D.S. one hour before meal and 1 gm nocte
Number of subjects: 66
Study 2092028 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 66
Study 328526 — intervention group
Group type: EXPERIMENTAL
Intervention: R-75 strain live, attenuated, serum inhibitor-resistant influenza B vaccine
Number of subjects: 21
Study 328526 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 21
Study 31483963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human GM-CSF (sargramostim), 125 μg twice daily for 7 days, every other week for 24 weeks
Number of subjects: 64
Study 31483963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 31483963 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant human GM-CSF (sargramostim)
Number of subjects: 64
Study 28599016 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Strength Training (SST)
Number of subjects: 23